Inozyme Pharma has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $64,500,000.00 in Post-IPO Equity.
According to filings with the U.S. Securities and Exchange Commission, Inozyme Pharma is raising $64,500,000.00 in new funding. About Inozyme Pharma: Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
To learn more about Inozyme Pharma, visit http://www.inozyme.com/
Contact:
Douglas Treco, Chief Executive Officer
857-330-4340
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.